July 12, 2020

The Niche

Knoepfler lab stem cell blog

CIRM clinical trials

9 min read

When I think of the promise of stem cells for diabetes, the privately held California stem cell firm ViaCyte is the first biotech that comes to mind now. It has promising stem cell clinical trial work building. Today’s post is a new interview with the company’s CEO Paul Laikind. For past posts on ViaCyte see here, which includes an interview with Laikind a few years ago. PK: The last time we talked was in March 2015. Can you please update us on the VC-01 trial? How …Read More